PDL BioPharma (PDL BioPharma) Total Inventories : $12.63 Mil (As of Jun. 2020)

View and export this data going back to 1992. Start your Free Trial

What is PDL BioPharma Total Inventories?

PDL BioPharma's total inventories for the quarter that ended in Jun. 2020 was $12.63 Mil. PDL BioPharma's average total inventories from the quarter that ended in Mar. 2020 to the quarter that ended in Jun. 2020 was $11.59 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. PDL BioPharma's Net-Net Working Capital per share for the quarter that ended in Jun. 2020 was $0.14.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. PDL BioPharma's Days Inventory for the three months ended in Jun. 2020 was 400.67.

Inventory Turnover measures how fast the company turns over its inventory within a year. PDL BioPharma's Inventory Turnover for the quarter that ended in Jun. 2020 was 0.23.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. PDL BioPharma's Inventory-to-Revenue for the quarter that ended in Jun. 2020 was 2.22.

PDL BioPharma Total Inventories Historical Data

The historical data trend for PDL BioPharma's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PDL BioPharma Total Inventories Chart

PDL BioPharma Annual Data

Trend

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Total Inventories

Get a 7-Day Free Trial

2.88

9.15

18.94

39.77

PDL BioPharma Quarterly Data
	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20
Total Inventories	Get a 7-Day Free Trial															16.26	20.94	39.77	10.54	12.63

PDL BioPharma Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

PDL BioPharma (NAS:PDLI) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

PDL BioPharma's Net-Net Working Capital Per Share for the quarter that ended in Jun. 2020 is

	Net-Net Working Capital Per Share (Q: Jun. 2020 )
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(105.446	+	0.75 * 6.154	+	0.5 * 12.633	-	100.655
-	0	-	-0.467)	/	113.945
=	0.14

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

PDL BioPharma's Days Inventory for the three months ended in Jun. 2020 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Jun. 2020 )	/	Cost of Goods Sold (Q: Jun. 2020 )	*	Days in Period
	=	11.5875	/	2.639	*	365 / 4
	=	400.67

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

PDL BioPharma's Inventory Turnover for the quarter that ended in Jun. 2020 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Jun. 2020 )	/	Average Total Inventories (Q: Jun. 2020 )
	=	2.639	/	11.5875
	=	0.23

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

PDL BioPharma's Inventory to Revenue for the quarter that ended in Jun. 2020 is calculated as

Inventory-to-Revenue	=	Average Total Inventories (Q: Jun. 2020 )	/	Revenue (Q: Jun. 2020 )
	=	11.5875	/	5.211
	=	2.22

Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.

PDL BioPharma Total Inventories Related Terms

Thank you for viewing the detailed overview of PDL BioPharma's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.

PDL BioPharma (PDL BioPharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PDL BioPharma Inc (NAS:PDLI) » Definitions » Total Inventories

Comparable Companies

Traded in Other Exchanges

N/A

Address

932 Southwood Boulevard, Incline Villiage, NV, USA, 89451

Website

http://www.pdl.com

PDL BioPharma Inc acquires and manages a portfolio of companies, products, royalty agreements and debt facilities in the biotech, pharmaceutical and medical device industries. The operating segments of the company are Medical Devices, Strategic Positions, Pharmaceutical and Income Generating Assets, of which key revenue is derived from the Pharmaceutical segment. The Pharmaceutical segment consists of revenue derived from branded prescription medicine products sold under the name Tekturna and Tekturna HCT in the U.S, and Rasilez and Rasilez HCT in the rest of the world (collectively, the Noden Products). Geographically, the company operates in Europe, North America, Asia and Other countries, of which prime revenue is generated from Asia and North America.

Executives

David W Gryska	director	749 N MARY AVE, SUNNYVALE CA 94085
John Peter Mclaughlin	director	C/O PDL BIOPHARMA, INC., 932 SOUTHWOOD BOULEVARD, INCLINE VILLAGE NV 89451
Dominique Monnet	officer: President and CEO	C/O ALEXION PHARMACEUTICALS, INC., 352 KNOTTER DRIVE, CHESHIRE CT 06410
Christopher Lewis Stone	officer: VP, Gen. Counsel & Secretary	932 SOUTHWOOD BLVD. INCLINE VILLAGE NV 89451
Alan Lee Bazaar	director	9 BEDFORD ROAD, KATONAH NY 10536
Natasha Hernday	director	932 SOUTHWOOD BLVD, INCLINE VILLAGE NV 89451
Edward Imbrogno	officer: VP Finance, CAO and Acting CFO	932 SOUTHWOOD BLVD. INCLINE VILLAGE NV 89451
Jill M. Jene	officer: VP, Business Development	932 SOUTHWOOD BLVD., INCLINE VILLAGE NV 89451
Harold E Selick	director
Samuel R Saks	director	3180 PORTER DRIVE, PALO ALTO CA 94304
Paul W Sandman	director	C/O PDL BIOPHARMA, INC., 932 SOUTHWOOD BLVD, INCLINE VILLAGE NV 89451
Shlomo Yanai	director	ONE MEADOWLANDS PLAZA, EAST RUTHERFORD NJ 07073
Peter S Garcia	officer: Vice President, CFO	ALX ONCOLOGY HOLDINGS INC., 866 MALCOLM ROAD, SUITE 100, BURLINGAME CA 94010
Jody S Lindell	director	2536 FILLMORE ST., SAN FRANCISCO CA 94115
Paul R Edick	director	C/O NEWLINK GENETICS CORP., 2503 SOUTH LOOP DR., SUITE 5100, AMES IA 50010